HELP

Cybin D/B/A Helus Pharma

Cybin D/B/A Helus Pharma (HELP) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
B+
Factor Score 3.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.3
EV / EBITDA -3.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -18.0%
Price Return 12M 47.6%
Catalyst Signal 0.00
Market Cap $686.1M
TTM Revenue N/A
Price / Sales N/A
ROE -86.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C+ (2.6) C (2.4) B+ (3.6) C+ (2.6) C+ (2.7)
2026-11-05 C+ (2.5) C+ (2.5) C (2.4) B+ (3.5) C+ (2.7) C+ (2.7)
2026-10-29 C+ (2.5) C (2.5) C (2.4) A+ (4.5) C+ (2.7) B- (2.9)
2026-10-22 C+ (2.5) C (2.4) C (2.4) A+ (4.7) C+ (2.6) B- (2.9)
2026-10-15 C+ (2.5) C (2.3) C (2.4) A+ (4.8) C+ (2.6) B- (2.9)
Page 1 of 4